TGF-β - an excellent servant but a bad master

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Kubiczkova, Lenka ^a   Sedlarikova, Lenka ^a   Hajek, Roman ^a   Sevcikova, Sabina ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Leukemia; Multiple myeloma; Oncogene; SMAD proteins; Solid tumors; Suppressor; TGF

Indexed keywords

ANTINEOPLASTIC AGENT; ENDOGLIN; LY 2109761; SMAD PROTEIN; SMAD2 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG;

BINDING AFFINITY; BRAIN TUMOR; BREAST CANCER; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DIMERIZATION; DRUG EFFICACY; GENE MUTATION; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHATIC LEUKEMIA; METASTASIS; MISSENSE MUTATION; MULTIPLE MYELOMA; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERIPHERAL T CELL LYMPHOMA; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; SOLID TUMOR; STOMACH CANCER; SUMOYLATION; TUMOR MICROENVIRONMENT; UBIQUITINATION; UROGENITAL TRACT TUMOR;

HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84865597197     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-183     Document Type: Review

References (281)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674. 10.1016/j.cell.2011.02.013, 21376230.
2. Tian M, Neil JR, Schiemann WP. Transforming growth factor-β and the hallmarks of cancer. Cell Signal 2011, 23:951-962. 10.1016/j.cellsig.2010.10.015, 3076078, 20940046.
3. Derynck R. The TGF-β Family.: Cold Spring Harbor Laboratory 2008, Press.
4. Sporn MB, Todaro GJ. Autocrine secretion and malignant transformation of cells. N Engl J Med 1980, 303:878-880. 10.1056/NEJM198010093031511, 7412807.
5. de Larco JE, Todaro GJ. Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci USA 1978, 75:4001-4005. 10.1073/pnas.75.8.4001, 392918, 211512.
6. Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB. New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastictissues. Proc Natl Acad Sci USA 1981, 78:5339-5343. 10.1073/pnas.78.9.5339, 348740, 6975480.
7. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesisin vivoand stimulation of collagen formationin vitro. Proc. Natl. Acad. Sci. USA 1986, 83:4167-4171. 10.1073/pnas.83.12.4167, 323692, 2424019.
8. Tucker RF, Shipley GD, Moses HL, Holley RW. Growth inhibitor from BSC-1 cells closely related to platelet type β transforming growth factor. Science 1984, 226:705-707. 10.1126/science.6093254, 6093254.
9. Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB. Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci 1985, 82:119-123. 10.1073/pnas.82.1.119, 396983, 3871521.
10. Massagué J, Blain SW, Lo RS. TGF[beta] signaling in growth control, cancer, and heritable disorders. Cell 2000, 103:295-309. 10.1016/S0092-8674(00)00121-5, 11057902.
11. Patterson GI, Padgett RW. TGF beta-related pathways. Roles in Caenorhabditis elegans development. Trends Genet 2000, 16:27-33. 10.1016/S0168-9525(99)01916-2, 10637628.
12. Ohta M, Greenberger JS, Anklesaria P, Bassols A, Massagué J. Two forms of transforming growth factor-beta distinguished by multipotential haematopoieticprogenitor cells. Nature 1987, 329:539-541. 10.1038/329539a0, 2889143.
13. Cheifetz S, Weatherbee JA, Tsang ML, Anderson JK, Mole JE, Lucas R, Massagué J. The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors. Cell 1987, 48:409-415. 10.1016/0092-8674(87)90192-9, 2879635.
14. Mittl PR, Priestle JP, Cox DA, McMaster G, Cerletti N, Grütter MG. The crystal structure of TGF-beta 3 and comparison to TGF-beta 2: implications for receptorbinding. Protein Sci 1996, 5:1261-1271. 10.1002/pro.5560050705, 2143453, 8819159.
15. Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB, Goeddel DV. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature 1985, 316:701-705. 10.1038/316701a0, 3861940.
16. Dickinson ME, Kobrin MS, Silan CM, Kingsley DM, Justice MJ, Miller DA, Ceci JD, Lock LF, Lee A, Buchberg AM. Chromosomal localization of seven members of the murine TGF-beta superfamily suggests close linkage to several morphogenetic mutantloci. Genomics 1990, 6:505-520. 10.1016/0888-7543(90)90480-I, 1970330.
17. Flanders KC, Lüdecke G, Engels S, Cissel DS, Roberts AB, Kondaiah P, Lafyatis R, Sporn MB, Unsicker K. Localization and actions of transforming growth factor-beta s in the embryonic nervous system. Development 1991, 113:183-191.
18. de Martin R, Haendler B, Hofer-Warbinek R, Gaugitsch H, Wrann M, Schlüsener H, Seifert JM, Bodmer S, Fontana A, Hofer E. Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforminggrowth factor-beta gene family. EMBO J 1987, 6:3673-3677. 553836, 3322813.
19. ten Dijke P, Hansen P, Iwata KK, Pieler C, Foulkes JG. Identification of another member of the transforming growth factor type beta gene family. Proc Natl Acad Sci USA 1988, 85:4715-4719. 10.1073/pnas.85.13.4715, 280506, 3164476.
20. Proetzel G, Pawlowski SA, Wiles MV, Yin M, Boivin GP, Howles PN, Ding J, Ferguson MW, Doetschman T. Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet 1995, 11:409-414. 10.1038/ng1295-409, 7493021.
21. Kaartinen V, Voncken JW, Shuler C, Warburton D, Bu D, Heisterkamp N, Groffen J. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet 1995, 11:415-421. 10.1038/ng1295-415, 7493022.
22. Dubois CM, Laprise M-H, Blanchette F, Gentry LE, Leduc R. Processing of transforming growth factor 1 Precursor by human furin convertase. J Biol Chem 1995, 270:10618-10624. 10.1074/jbc.270.18.10618, 7737999.
23. Gray AM, Mason AJ. Requirement for activin A and transforming growth factor- beta 1 pro-regions in homodimer assembly. Science 1990, 247:1328-1330. 10.1126/science.2315700, 2315700.
24. Miyazono K, Hellman U, Wernstedt C. Heldin CH: Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. J Biol Chem 1988, 263:6407-6415.
25. Gleizes PE, Beavis RC, Mazzieri R, Shen B, Rifkin DB. Identification and characterization of an eight-cysteine repeat of the latent transforming growth factorbetabinding protein-1 that mediates bonding to the latent transforming growth factorbeta1. J Biol Chem 1996, 271:29891-29896. 10.1074/jbc.271.47.29891, 8939931.
26. Taipale J, Miyazono K, Heldin CH, Keski-Oja J. Latent transforming growth factorbeta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J Cell Biol 1994, 124:171-181. 10.1083/jcb.124.1.171, 2119892, 8294500.
27. Kojima S, Nara K, Rifkin DB. Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells. J Cell Biol 1993, 121:439-448. 10.1083/jcb.121.2.439, 2200108, 8096847.
28. Flaumenhaft R, Abe M, Mignatti P, Rifkin DB. Basic fibroblast growth factor-induced activation of latent transforming growth factor beta in endothelial cells: regulation ofplasminogen activator activity. J Cell Biol 1992, 118:901-909. 10.1083/jcb.118.4.901, 2289566, 1380001.
29. Nunes I, Shapiro RL, Rifkin DB. Characterization of latent TGF-beta activation by murine peritoneal macrophages. J Immunol 1995, 155:1450-1459.
30. Sato Y, Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule byplasmin during co-culture. J Cell Biol 1989, 109:309-315. 10.1083/jcb.109.1.309, 2115489, 2526131.
31. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000, 14:163-176. 316345, 10652271.
32. Schultz-Cherry S, Murphy-Ullrich JE. Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J Cell Biol 1993, 122:923-932. 10.1083/jcb.122.4.923, 2119591, 8349738.
33. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999, 96:319-328. 10.1016/S0092-8674(00)80545-0, 10025398.
34. Mu D, Cambier S, Fjellbirkeland L, Baron JL, Munger JS, Kawakatsu H, Sheppard D, Broaddus VC, Nishimura SL. The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J Cell Biol 2002, 157:493-507. 10.1083/jcb.200109100, 2173277, 11970960.
35. Barcellos-Hoff MH, Dix TA. Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol 1996, 10:1077-1083. 10.1210/me.10.9.1077, 8885242.
36. Lyons RM, Keski-Oja J, Moses HL. Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J Cell Biol 1988, 106:1659-1665. 10.1083/jcb.106.5.1659, 2115066, 2967299.
37. Cheifetz S, Like B, Massagué J. Cellular distribution of type I and type II receptors for transforming growth factor-beta. J Biol Chem 1986, 261:9972-9978.
38. Cheifetz S, Andres JL, Massagué J. The transforming growth factor-beta receptor type III is a membrane proteoglycan. Domain structure of the receptor. J Biol Chem 1988, 263:16984-16991.
39. Cheifetz S, Bellón T, Calés C, Vera S, Bernabeu C, Massagué J, Letarte M. Endoglin is a component of the transforming growth factor-beta receptor system in humanendothelial cells. J Biol Chem 1992, 267:19027-19030.
40. Segarini PR, Rosen DM, Seyedin SM. Binding of transforming growth factor-beta to cell surface proteins varies with cell type. Mol Endocrinol 1989, 3:261-272. 10.1210/mend-3-2-261, 2710133.
41. Gougos A, Letarte M. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 1990, 265:8361-8364.
42. Robledo MM, Ursa MA, Sánchez-Madrid F, Teixidó J. Associations between TGFbeta1 receptors in human bone marrow stromal cells. Br J Haematol 1998, 102:804-811. 10.1046/j.1365-2141.1998.00820.x, 9722311.
43. Matsubara S, Bourdeau A, terBrugge KG, Wallace C, Letarte M. Analysis of endoglin expression in normal brain tissue and in cerebral arteriovenous malformations. Stroke 2000, 31:2653-2660. 10.1161/01.STR.31.11.2653, 11062290.
44. Henry LA, Johnson DA, Sarrió D, Lee S, Quinlan PR, Crook T, Thompson AM, Reis- Filho JS, Isacke CM. Endoglin expression in breast tumor cells suppresses invasion and metastasis and correlates with improved clinical outcome. Oncogene 2011, 30:1046-1058. 10.1038/onc.2010.488, 21042283.
45. Sandlund J, Hedberg Y, Bergh A, Grankvist K, Ljungberg B, Rasmuson T. Endoglin (CD105) expression in human renal cell carcinoma. BJU Int 2006, 97:706-710. 10.1111/j.1464-410X.2006.06006.x, 16536758.
46. Esparza-Lopez J, Montiel JL, Vilchis-Landeros MM, Okadome T, Miyazono K, López- Casillas F. Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions fortransforming growth factor-beta and inhibin A. J Biol Chem 2001, 276:14588-14596. 10.1074/jbc.M008866200, 11278442.
47. López-Casillas F, Wrana JL, Massagué J. Betaglycan presents ligand to the TGF beta signaling receptor. Cell 1993, 73:1435-1444. 10.1016/0092-8674(93)90368-Z, 8391934.
48. Yamashita H, Ichijo H, Grimsby S, Morén A, ten Dijke P, Miyazono K. Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factorbeta. J Biol Chem 1994, 269:1995-2001.
49. Massagué J. Receptors for the TGF-beta family. Cell 1992, 69:1067-1070.
50. Lu S-L, Zhang W-C, Akiyama Y, Nomizu T, Yuasa Y. Genomic structure of the transforming growth factor β Type II receptor gene and its mutations in hereditarynonpolyposis colorectal cancers. Cancer Res 1996, 56:4595-4598.
51. Sun PD, Davies DR. The cystine-knot growth-factor superfamily. Annu Rev Biophys Biomol Struct 1995, 24:269-291. 10.1146/annurev.bb.24.060195.001413, 7663117.
52. Shi Y, Massagué J. Mechanisms of TGF-[beta] Signaling from Cell Membrane to the Nucleus. Cell 2003, 113:685-700. 10.1016/S0092-8674(03)00432-X, 12809600.
53. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. Mechanism of activation of the TGF-beta receptor. Nature 1994, 370:341-347. 10.1038/370341a0, 8047140.
54. Derynck R, Feng X-H. TGF-[beta] receptor signaling.Biochimica et Biophysica Acta (BBA). Reviews on Cancer 1997, 1333:F105-F150.
55. Finnson KW, Parker WL, Chi Y, Hoemann CD, Goldring MB, Antoniou J, Philip A. Endoglin differentially regulates TGF-β-induced Smad2/3 and Smad1/5 signalling and its expression correlates with extracellular matrix production and cellulardifferentiation state in human chondrocytes. Osteoarthr Cartil 2010, 18:1518-1527. 10.1016/j.joca.2010.09.002, 20833252.
56. Kerscher O, Felberbaum R, Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 2006, 22:159-180. 10.1146/annurev.cellbio.22.010605.093503, 16753028.
57. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, Wrana JL. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 2000, 6:1365-1375. 10.1016/S1097-2765(00)00134-9, 11163210.
58. Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, Imamura T, Miyazono K. Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem 2001, 276:12477-12480. 10.1074/jbc.C100008200, 11278251.
59. Kang JS, Saunier EF, Akhurst RJ, Derynck R. The type I TGF-beta receptor is covalently modified and regulated by sumoylation. Nat Cell Biol 2008, 10:654-664. 10.1038/ncb1728, 2649123, 18469808.
60. Chen YG. Endocytic regulation of TGF-beta signaling. Cell Res 2009, 19:58-70. 10.1038/cr.2008.315, 19050695.
61. Attisano L, Wrana JL. Smads as transcriptional co-modulators. Curr Opin Cell Biol 2000, 12:235-243. 10.1016/S0955-0674(99)00081-2, 10712925.
62. Liu F, Hata A, Baker JC, Doody J, Cárcamo J, Harland RM, Massagué J. A human Mad protein acting as a BMP-regulated transcriptional activator. Nature 1996, 381:620-623. 10.1038/381620a0, 8637600.
63. Massagué J, Seoane J, Wotton D. Smad transcription factors. Genes & Development 2005, 19:2783-2810.
64. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu Y-Y, Grinnell BW, Richardson MA, Topper JN, Gimbrone MA, Wrana JL, Falb D. The MAD-related protein smad7 associates with the TGF[beta] receptor and Functions as an antagonist of TGF[beta] signaling. Cell 1997, 89:1165-1173. 10.1016/S0092-8674(00)80303-7, 9215638.
65. Hata A, Lagna G, Massagué J, Hemmati-Brivanlou A. Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev 1998, 12:186-197. 10.1101/gad.12.2.186, 316444, 9436979.
66. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL. SARA, a FYVE Domain Protein that Recruits Smad2 to the TGF[beta] Receptor. Cell 1998, 95:779-791. 10.1016/S0092-8674(00)81701-8, 9865696.
67. Watanabe Y, Itoh S, Goto T, Ohnishi E, Inamitsu M, Itoh F, Satoh K, Wiercinska E, Yang W, Shi L, et al. TMEPAI, a transmembrane TGF-beta-inducible protein, sequesters Smad proteins from active participation in TGF-beta signaling. Mol Cell 2010, 37:123-134. 10.1016/j.molcel.2009.10.028, 20129061.
68. Wu JW, Hu M, Chai J, Seoane J, Huse M, Li C, Rigotti DJ, Kyin S, Muir TW, Fairman R, et al. Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling. Mol Cell 2001, 8:1277-1289. 10.1016/S1097-2765(01)00421-X, 11779503.
69. Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 1999, 400:687-693. 10.1038/23293, 10458166.
70. Xiao Z, Liu X, Henis YI, Lodish HF. A distinct nuclear localization signal in the N terminus of Smad 3 determines its ligand-induced nuclear translocation. Proc Natl Acad Sci USA 2000, 97:7853-7858. 10.1073/pnas.97.14.7853, 16634, 10884415.
71. Xu L, Chen YG, Massagué J. The nuclear import function of Smad2 is masked by SARA and unmasked by TGFbeta-dependent phosphorylation. Nat Cell Biol 2000, 2:559-562. 10.1038/35019649, 10934479.
72. Xu L, Kang Y, Cöl S, Massagué J. Smad2 nucleocytoplasmic shuttling by nucleoporins CAN/Nup214 and Nup153 feeds TGFbeta signaling complexes in thecytoplasm and nucleus. Mol Cell 2002, 10:271-282. 10.1016/S1097-2765(02)00586-5, 12191473.
73. Inman GJ, Nicolás FJ, Hill CS. Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-beta receptor activity. Mol Cell 2002, 10:283-294. 10.1016/S1097-2765(02)00585-3, 12191474.
74. Chen CR, Kang Y, Massagué J. Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci USA 2001, 98:992-999. 10.1073/pnas.98.3.992, 14697, 11158583.
75. Zavadil J, Bitzer M, Liang D, Yang YC, Massimi A, Kneitz S, Piek E, Bottinger EP. Genetic programs of epithelial cell plasticity directed by transforming growth factorbeta. Proc Natl Acad Sci USA 2001, 98:6686-6691. 10.1073/pnas.111614398, 34413, 11390996.
76. Feng X-H, Zhang Y, Wu R-Y, Derynck R. The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for Smad3 in TGF-β-inducedtranscriptional activation. Genes Dev 1998, 12:2153-2163. 10.1101/gad.12.14.2153, 317015, 9679060.
77. Pouponnot C, Jayaraman L, Massagué J. Physical and Functional Interaction of SMADs and p300/CBP. J Biol Chem 1998, 273:22865-22868. 10.1074/jbc.273.36.22865, 9722503.
78. Pearson KL, Hunter T, Janknecht R. Activation of Smad1-mediated transcription by p300/CBP.Biochimica et Biophysica Acta (BBA). Gene Structure and Expression 1999, 1489:354-364.
79. Topper JN, DiChiara MR, Brown JD, Williams AJ, Falb D, Collins T, Gimbrone MA. CREB binding protein is a required coactivator for Smad-dependent, transforming growth factor β transcriptional responses in endothelial cells. Proc Natl Acad Sci 1998, 95:9506-9511. 10.1073/pnas.95.16.9506, 21368, 9689110.
80. Ross S, Hill CS. How the Smads regulate transcription. Int J Biochem Cell Biol 2008, 40:383-408. 10.1016/j.biocel.2007.09.006, 18061509.
81. Davis BN, Hilyard AC, Nguyen PH, Lagna G, Hata A. Smad proteins bind a conserved RNA sequence to promote MicroRNA maturation by Drosha. Mol Cell 2010, 39:373-384. 10.1016/j.molcel.2010.07.011, 2921543, 20705240.
82. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008, 454:56-61. 10.1038/nature07086, 2653422, 18548003.
83. Moustakas A, Heldin C-H. Non-Smad TGF-β signals. J Cell Sci 2005, 118:3573-3584. 10.1242/jcs.02554, 16105881.
84. Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL. p38 mitogen-activated protein kinase is required for TGFβ-mediated fibroblastic transdifferentiation and cellmigration. J Cell Sci 2002, 115:3193-3206.
85. Engel ME, McDonnell MA, Law BK, Moses HL. Interdependent SMAD and JNK signaling in transforming growth factor-β-mediated transcription. J Biol Chem 1999, 274:37413-37420. 10.1074/jbc.274.52.37413, 10601313.
86. Yu L, Hébert MC, Zhang YE. TGF-β receptor-activated p38 MAP kinase mediates Smad-independent TGF-β responses. EMBO J 2002, 21:3749-3759. 10.1093/emboj/cdf366, 126112, 12110587.
87. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. Phosphatidylinositol 3-kinase function is required for transforming growth factor β- mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 2000, 275:36803-36810. 10.1074/jbc.M005912200, 10969078.
88. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL. Transforming growth factor-β1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 2001, 12:27-36. 30565, 11160820.
89. Lamouille S, Derynck R. Cell size and invasion in TGF-β-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 2007, 178:437-451. 10.1083/jcb.200611146, 2064840, 17646396.
90. Horowitz JC, Rogers DS, Sharma V, Vittal R, White ES, Cui Z, Thannickal VJ. Combinatorial activation of FAK and AKT by transforming growth factor-β1 confers an anoikis-resistant phenotype to myofibroblasts. Cell Signal 2007, 19:761-771. 10.1016/j.cellsig.2006.10.001, 1820832, 17113264.
91. Galliher AJ, Schiemann WP. β3 Integrin and Src facilitate transforming growth factor-β mediated induction of epithelial-mesenchymal transition in mammaryepithelial cells. Breast Cancer Res 2006, 8(4):R42. 10.1186/bcr1524, 1779461, 16859511.
92. Park SS, Eom Y-W, Kim EH, Lee JH, Min DS, Kim S, Kim S-J, Choi KS. Involvement of c-Src kinase in the regulation of TGF-[beta]1-induced apoptosis. Oncogene 2004, 23:6272-6281. 10.1038/sj.onc.1207856, 15208664.
93. Gingery A, Bradley EW, Pederson L, Ruan M, Horwood NJ, Oursler MJ. TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promoteosteoclast survival. Exp Cell Res 2008, 314:2725-2738. 10.1016/j.yexcr.2008.06.006, 2578840, 18586026.
94. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001, 29:117-129. 10.1038/ng1001-117, 11586292.
95. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006, 6:506-520. 10.1038/nrc1926, 16794634.
96. Pangas SA, Matzuk MM. Genetic models for transforming growth factor beta superfamily signaling in ovarian follicle development. Mol Cell Endocrinol 2004, 225:83-91. 10.1016/j.mce.2004.02.017, 15451572.
97. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, Akhurst RJ. TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasivespindle carcinomas in transgenic mice. Cell 1996, 86:531-542. 10.1016/S0092-8674(00)80127-0, 8752208.
98. Amendt C, Schirmacher P, Weber H, Blessing M. Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidenceand an acceleration of carcinoma development. Oncogene 1998, 17:25-34. 10.1038/sj.onc.1202161, 9671311.
99. Wang XJ, Liefer KM, Tsai S, O'Malley BW, Roop DR. Development of gene-switch transgenic mice that inducibly express transforming growth factor beta1 in theepidermis. Proc Natl Acad Sci USA 1999, 96:8483-8488. 10.1073/pnas.96.15.8483, 17542, 10411901.
100. Weeks BH, He W, Olson KL, Wang XJ. Inducible expression of transforming growth factor beta1 in papillomas causes rapid metastasis. Cancer Res 2001, 61:7435-7443.
101. Hannon GJ. Beach D: pl5INK4B is a potentia| effector of TGF-[beta]-induced cell cycle arrest. Nature 1994, 371:257-261. 10.1038/371257a0, 8078588.
102. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 1995, 92:5545-5549. 10.1073/pnas.92.12.5545, 41732, 7777546.
103. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition tocell cycle arrest. Genes Dev 1994, 8:9-22. 10.1101/gad.8.1.9, 8288131.
104. Kang Y, Chen C-R, Massagué J. A self-enabling TGF[beta] response coupled to stress signaling: smad engages stress response factor ATF3 for Id1 repression inepithelial cells. Mol Cell 2003, 11:915-926. 10.1016/S1097-2765(03)00109-6, 12718878.
105. Isoe S, Naganuma H, Nakano S, Sasaki A, Satoh E, Nagasaka M, Maeda S, Nukui H. Resistance to growth inhibition by transforming growth factor-β in malignant glioma cells with functional receptors. J Neurosurg 1998, 88:529-534. 10.3171/jns.1998.88.3.0529, 9488308.
106. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13:1501-1512. 10.1101/gad.13.12.1501, 10385618.
107. Reynisdóttir I, Massagué J. The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev 1997, 11:492-503. 10.1101/gad.11.4.492, 9042862.
108. Sandhu C, Garbe J, Bhattacharya N, Daksis J, Pan CH, Yaswen P, Koh J, Slingerland JM, Stampfer MR. Transforming growth factor beta stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in humanmammary epithelial cells. Mol Cell Biol 1997, 17:2458-2467. 232094, 9111314.
109. Iavarone A, Massague J. E2F and histone deacetylase mediate transforming growth factor beta repression of cdc25A during keratinocyte cell cycle arrest. Mol Cell Biol 1999, 19:916-922. 83949, 9858615.
110. Chen C-R, Kang Y, Siegel PM, Massagué J. E2F4/5 and p107 as smad cofactors linking the TGF[beta] Receptor to c-myc Repression. Cell 2002, 110:19-32. 10.1016/S0092-8674(02)00801-2, 12150994.
111. Levy L, Hill CS. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 2006, 17:41-58. 10.1016/j.cytogfr.2005.09.009, 16310402.
112. Teicher BA. Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev 2001, 20:133-143. 10.1023/A:1013177011767, 11831642.
113. Biswas S, Chytil A, Washington K, Romero-Gallo J, Gorska AE, Wirth PS, Gautam S, Moses HL, Grady WM. Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer. Cancer Res 2004, 64:4687-4692. 10.1158/0008-5472.CAN-03-3255, 15256431.
114. Gobbi H, Arteaga CL, Jensen RA, Simpson JF, Dupont WD, Olson SJ, Schuyler PA, Plummer WD, Page DL. Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasivecarcinomas. Histopathology 2000, 36:168-177. 10.1046/j.1365-2559.2000.00841.x, 10672063.
115. Bardeesy N, Cheng K-H, Berger JH, Chu GC, Pahler J, Olson P, Hezel AF, Horner J, Lauwers GY, Hanahan D, DePinho RA. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 2006, 20:3130-3146. 10.1101/gad.1478706, 1635148, 17114584.
116. Muñoz-Antonia T, Torrellas-Ruiz M, Clavell J, Mathews LA, Muro-Cacho CA, Báez A. Aberrant methylation inactivates transforming growth factor Beta receptor I in head and neck squamous cell carcinoma. Int. J. Otolaryngol 2009, 2009:848695-848695. 2809419, 20111589.
117. Lu SL, Herrington H, Reh D, Weber S, Bornstein S, Wang D, Li AG, Tang CF, Siddiqui Y, Nord J, et al. Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev 2006, 20:1331-1342. 10.1101/gad.1413306, 1472907, 16702406.
118. Kuratomi G, Komuro A, Goto K, Shinozaki M, Miyazawa K, Miyazono K, Imamura T. NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-beta (transforming growth factor-beta) signalling by inducingubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor. Biochem J 2005, 386:461-470. 10.1042/BJ20040738, 1134864, 15496141.
119. Komuro A, Imamura T, Saitoh M, Yoshida Y, Yamori T, Miyazono K, Miyazawa K. Negative regulation of transforming growth factor-beta (TGF-beta) signaling by WW domain-containing protein 1 (WWP1). Oncogene 2004, 23:6914-6923. 10.1038/sj.onc.1207885, 15221015.
120. Fukuchi M, Fukai Y, Masuda N, Miyazaki T, Nakajima M, Sohda M, Manda R, Tsukada K, Kato H, Kuwano H. High-level expression of the Smad ubiquitin ligase Smurf2 correlates with poor prognosis in patients with esophageal squamous cellcarcinoma. Cancer Res 2002, 62:7162-7165.
121. Kim SJ, Im YH, Markowitz SD, Bang YJ. Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis. Cytokine Growth Factor Rev 2000, 11:159-168. 10.1016/S1359-6101(99)00039-8, 10708963.
122. Kang SH, Bang YJ, Im YH, Yang HK, Lee DA, Lee HY, Lee HS, Kim NK, Kim SJ. Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-beta resistance in humangastric cancer. Oncogene 1999, 18:7280-7286. 10.1038/sj.onc.1203146, 10602482.
123. Hinshelwood RA, Huschtscha LI, Melki J, Stirzaker C, Abdipranoto A, Vissel B, Ravasi T, Wells CA, Hume DA, Reddel RR, Clark SJ. Concordant epigenetic silencing of transforming growth factor-beta signaling pathway genes occurs early in breastcarcinogenesis. Cancer Res 2007, 67:11517-11527. 10.1158/0008-5472.CAN-07-1284, 18089780.
124. Bristow RG, Hill RP. Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008, 8:180-192. 10.1038/nrc2344, 18273037.
125. Mareel M, Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 2003, 83:337-376.
126. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004, 303:848-851. 10.1126/science.1090922, 14764882.
127. Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, Arteaga CL, Neilson EG, Hayward SW, Moses HL. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGFalpha-,MSP- and HGF-mediated signaling networks. Oncogene 2005, 24:5053-5068. 10.1038/sj.onc.1208685, 3074577, 15856015.
128. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR, Massagué J. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008, 133:66-77. 10.1016/j.cell.2008.01.046, 2390892, 18394990.
129. Bierie B, Stover DG, Abel TW, Chytil A, Gorska AE, Aakre M, Forrester E, Yang L, Wagner KU, Moses HL. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res 2008, 68:1809-1819. 10.1158/0008-5472.CAN-07-5597, 18339861.
130. Lee MS, Kim TY, Kim YB, Lee SY, Ko SG, Jong HS, Bang YJ, Lee JW. The signaling network of transforming growth factor beta1, protein kinase Cdelta, and integrinunderlies the spreading and invasiveness of gastric carcinoma cells. Mol Cell Biol 2005, 25:6921-6936. 10.1128/MCB.25.16.6921-6936.2005, 1190263, 16055706.
131. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454. 10.1038/nrc822, 12189386.
132. Thiery JP, Chopin D. Epithelial cell plasticity in development and tumor progression. Cancer Metastasis Rev 1999, 18:31-42. 10.1023/A:1006256219004, 10505544.
133. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010, 31:220-227. 10.1016/j.it.2010.04.002, 2891151, 20538542.
134. Lebman DA, Edmiston JS. The role of TGF-beta in growth, differentiation, and maturation of B lymphocytes. Microbes Infect 1999, 1:1297-1304. 10.1016/S1286-4579(99)00254-3, 10611758.
135. Gilbert KM, Thoman M, Bauche K, Pham T, Weigle WO. Transforming growth factor-beta 1 induces antigen-specific unresponsiveness in naive T cells. Immunol Invest 1997, 26:459-472. 10.3109/08820139709022702, 9246566.
136. Bommireddy R, Ormsby I, Yin M, Boivin GP, Babcock GF, Doetschman T. TGF beta 1 inhibits Ca2 + -calcineurin-mediated activation in thymocytes. J Immunol 2003, 170:3645-3652. 2804068, 12646629.
137. Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N, Wahl LM, Roberts AB, Sporn MB. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 1987, 84:5788-5792. 10.1073/pnas.84.16.5788, 298948, 2886992.
138. Monteleone G, Mann J, Monteleone I, Vavassori P, Bremner R, Fantini M, Del Vecchio Blanco G, Tersigni R, Alessandroni L, Mann D, et al. A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gutinflammation. J Biol Chem 2004, 279:3925-3932.
139. Korpal M, Kang Y. Targeting the transforming growth factor-beta signalling pathway in metastatic cancer. Eur J Cancer 2010, 46:1232-1240. 10.1016/j.ejca.2010.02.040, 20307969.
140. Lampropoulos P, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. TGF-beta signalling in colon carcinogenesis. Cancer Lett 2012, 314:1-7. 10.1016/j.canlet.2011.09.041, 22018778.
141. Fakhrai H, Mantil JC, Liu L, Nicholson GL, Murphy-Satter CS, Ruppert J, Shawler DL. Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther 2006, 13:1052-1060. 10.1038/sj.cgt.7700975, 16826191.
142. Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cellvaccine in non-small-cell lung cancer. J Clin Oncol 2006, 24:4721-4730. 10.1200/JCO.2005.05.5335, 16966690.
143. Gadir N, Jackson DN, Lee E, Foster DA. Defective TGF-beta signaling sensitizes human cancer cells to rapamycin. Oncogene 2008, 27:1055-1062. 10.1038/sj.onc.1210721, 17700525.
144. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993, 90:770-774. 10.1073/pnas.90.2.770, 45747, 8421714.
145. Böttner M, Krieglstein K, Unsicker K. The transforming growth factor-betas: structure, signaling, and roles in nervous system development and functions. J Neurochem 2000, 75:2227-2240.
146. CBTRUS Central Brain Tumor Registry of the United States (CBTRUS): 2011 CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosedin the United States in 2004-2007 2007, http://www.cbtrus.org/2011-NPCR-SEER/WEB-0407- Report-3-3-2011.pdf, CBTRUS.
147. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK. The WHO classification of tumors of the nervous system. J Neuropath Exp Neur 2002, 61:215-225. discussion 226-229-215-225; discussion 226-229.
148. Izumoto S, Arita N, Ohnishi T, Hiraga S, Taki T, Tomita N, Ohue M, Hayakawa T. Microsatellite instability and mutated type II transforming growth factor-[beta] receptor gene in gliomas. Cancer Lett 1997, 112:251-256. 10.1016/S0304-3835(96)04583-1, 9066736.
149. Fujiwara K, Ikeda H, Yoshimoto T. Abnormalities in expression of genes, mRNA, and proteins of transforming growth factor-beta receptor type I and type II in humanpituitary adenomas. Clin Neuropathol 1998, 17:19-26.
150. Kjellman C, Olofsson SP, Hansson O, Von Schantz T, Lindvall M, Nilsson I, Salford LG, Sjögren HO, Widegren B. Expression of TGF-β isoforms, TGF-β receptors, and Smad molecules at different stages of human glioma. Int J Cancer 2000, 89:251-258. 10.1002/1097-0215(20000520)89:3<251::AID-IJC7>3.0.CO;2-5, 10861501.
151. Yamada N, Kato M, Yamashita H, Nister M, Miyazono K, Heldin CH, Funa K. Enhanced expression of transforming growth factor-β and its type-I and type-II receptors in human glioblastoma. Int J Cancer 1995, 62:386-392. 10.1002/ijc.2910620405, 7635563.
152. Jachimczak P, Hessdörfer B, Fabel-Schulte K, Wismeth C, Brysch W, Schlingensiepen KH, Bauer A, Blesch A, Bogdahn U. Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisenseoligonucleotides. Int. J. CancerJournal Int Du Cancer 1996, 65:332-337.
153. Zhang L, Sato E, Amagasaki K, Nakao A, Naganuma H. Participation of an abnormality in the transforming growth factor-β signaling pathway in resistance ofmalignant glioma cells to growth inhibition induced by that factor. J Neurosurg 2006, 105:119-128. 10.3171/jns.2006.105.1.119, 16871886.
154. Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, Seoane J. High TGFβ-smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B Gene. Cancer Cell 2007, 11:147-160. 10.1016/j.ccr.2006.11.023, 17292826.
155. Copland JA, Luxon BA, Ajani L, Maity T, Campagnaro E, Guo H, LeGrand SN, Tamboli P, Wood CG. Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis andprogression. Oncogene 2003, 22:8053-8062. 10.1038/sj.onc.1206835, 12970754.
156. Hung T-T, Wang H, Kingsley EA, Risbridger GP, Russell PJ. Molecular profiling of bladder cancer: Involvement of the TGF-[beta] pathway in bladder cancer progression. Cancer Lett 2008, 265:27-38. 10.1016/j.canlet.2008.02.034, 18477502.
157. Li Y, Yang K, Mao Q, Zheng X, Kong D, Xie L. Inhibition of TGF-β receptor I by siRNA suppresses the motility and invasiveness of T24 bladder cancer cells viamodulation of integrins and matrix metalloproteinase. Int Urol Nephrol 2009, 42:315-323.
158. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008, 34:193-205. 10.1016/j.ctrv.2007.12.001, 18313224.
159. Sjölund J, Boström AK, Lindgren D, Manna S, Moustakas A, Ljungberg B, Johansson M, Fredlund E, Axelson H. The Notch and TGF-β Signaling Pathways Contribute to the Aggressiveness of Clear Cell Renal Cell Carcinoma. PLoS One 2011, 6:e23057. 10.1371/journal.pone.0023057, 3149633, 21826227.
160. Komiyama S, Kurahashi T, Ishikawa M, Tanaka K, Komiyama M, Mikami M, Udagawa Y. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin. Oncol Rep 2011, 25:1131-1138.
161. Antony ML, Nair R, Sebastian P, Karunagaran D. Changes in expression, and/or mutations in TGF-β receptors (TGF-β RI and TGF-β RII) and Smad 4 in humanovarian tumors. J Cancer Res Clin Oncol 2009, 136:351-361.
162. Chen T, Triplett J, Dehner B, Hurst B, Colligan B, Pemberton J, Graff JR, Carter JH. Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas. Cancer Res 2001, 61:4679-4682.
163. Kaklamani VG, Hou N, Bian Y, Reich J, Offit K, Michel LS, Rubinstein WS, Rademaker A, Pasche B. TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol: Official Journal of the Am J Clin Oncol 2003, 21:3236-3243.
164. Biswas S, Trobridge P, Romero-Gallo J, Billheimer D, Myeroff LL, Willson JKV, Markowitz SD, Grady WM. Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonaloutgrowth of transforming growth factor beta resistant cells. Genes Chromosomes Cancer 2008, 47:95-106. 10.1002/gcc.20511, 17985359.
165. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawroz H, et al. DPC4 Gene in Various Tumor Types. Cancer Res 1996, 56:2527-2530.
166. Do T-V, Kubba LA, Du H, Sturgis CD, Woodruff TK. Transforming growth Factor-β1, transforming growth factor-β2, and transforming growth factor-β3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymaltransition. Mol Cancer Res 2008, 6:695-705. 10.1158/1541-7786.MCR-07-0294, 2927222, 18505915.
167. Chan MWY, Huang Y-W, Hartman-Frey C, Kuo C-T, Deatherage D, Qin H, Cheng ASL, Yan PS, Davuluri RV, Huang THM, et al. Aberrant Transforming Growth Factor β1 Signaling and SMAD4 Nuclear Translocation Confer Epigenetic Repression ofADAM19 in Ovarian Cancer. Neoplasia (New York, NY) 2008, 10:908-919.
168. Rodriguez GC, Haisley C, Hurteau J, Moser TL, Whitaker R, Bast RC, Stack MS. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-β. Gynecol Oncol 2001, 80:245-253. 10.1006/gyno.2000.6042, 11161867.
169. Yeh KT, Chen TH, Yang HW, Chou JL, Chen LY, Yeh CM, Chen YH, Lin RI, Su HY, Chen GCW, et al. Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer. Epigenetics: Official Journal of the DNA Methylation Society 2011, 6:727-739.
170. Kennedy BA, Deatherage DE, Gu F, Tang B, Chan MW, Nephew KP, Huang TH, Jin VX. ChIP-seq Defined Genome-Wide Map of TGFβ/SMAD4 Targets: Implications with Clinical Outcome of Ovarian Cancer. PLoS One 2011, 6:e22606. 10.1371/journal.pone.0022606, 3143154, 21799915.
171. Wikström P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome inprostate cancer. Prostate 1998, 37:19-29. 10.1002/(SICI)1097-0045(19980915)37:1<19::AID-PROS4>3.0.CO;2-3, 9721065.
172. Yu N, Kozlowski JM, Park II, Chen L, Zhang Q, Xu D, Doll JA, Crawford SE, Brendler CB, Lee C. Overexpression of transforming growth factor [beta]1 in malignant prostate cells is partly caused by a runaway of TGF-[beta]1 auto-induction mediated through adefective recruitment of protein phosphatase 2A by TGF-[beta] type I receptor. Urology 2010, 76:1519. e1518-1519.e1513-1519.e1518-1519.e1513, 2997920, 21030067.
173. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Lang S, Kato M, Oefelein MG, Miyazono K, Nemeth JA, Kozlowski JM, Lee C. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancertissues. Clin Cancer Res 1996, 2:1255-1261.
174. Guo Y, Jacobs SC, Kyprianou N. Down-regulation of protein and mRNA expression for transforming growth factor-β (TGF-β1) type I and type II receptors in humanprostate cancer. Int J Cancer 1997, 71:573-579. 10.1002/(SICI)1097-0215(19970516)71:4<573::AID-IJC11>3.0.CO;2-D, 9178810.
175. Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostatecancer. Cancer Res 2007, 67:1090-1098. 10.1158/0008-5472.CAN-06-3117, 17283142.
176. Zhang Q, Rubenstein JN, Jang TL, Pins M, Javonovic B, Yang X, Kim S-J, Park I, Lee C. Insensitivity to transforming growth factor-β results from promoter methylation of cognate receptors in human prostate cancer cells (LNCaP). Mol Endocrinol 2005, 19:2390-2399. 10.1210/me.2005-0096, 15905358.
177. Latil A, Pesche S, Valéri A, Fournier G, Cussenot O, Lidereau R. Expression and mutational analysis of the MADR2/smad2 gene in human prostate cancer. Prostate 1999, 40:225-231. 10.1002/(SICI)1097-0045(19990901)40:4<225::AID-PROS3>3.0.CO;2-3, 10420150.
178. Yin Z, Babaian RJ, Troncoso P, Strom SS, Spitz MR, Caudell JJ, Stein JD, Kagan J. Limiting the location of putative human prostate cancer tumor suppressor genes on chromosome 18q. Oncogene 2001, 20:2273-2280. 10.1038/sj.onc.1204310, 11402322.
179. Yang J, Wahdan-Alaswad R, Danielpour D. Critical role of smad2 in tumor suppression and transforming growth factor-β-induced apoptosis of prostate epithelialcells. Cancer Res 2009, 69:2185-2190. 10.1158/0008-5472.CAN-08-3961, 3345028, 19276350.
180. Robinson SD, Silberstein GB, Roberts AB, Flanders KC, Daniel CW. Regulated expression and growth inhibitory effects of transforming growth factor-beta isoforms inmouse mammary gland development. Development 1991, 113:867-878.
181. Serra R, Crowley MR. Mouse models of transforming growth factor beta impact in breast development and cancer. Endocr Relat Cancer 2005, 12:749-760. 10.1677/erc.1.00936, 16322320.
182. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987, 48:417-428. 10.1016/0092-8674(87)90193-0, 2879636.
183. Marrogi AJ, Munshi A, Merogi AJ, Ohadike Y, El Habashi A, Marrogi OL, Freeman SM. Study of tumor infiltrating lymphocytes and transforming growth factor β as prognostic factors in breast carcinoma. Int J Cancer 1997, 74:492-501. 10.1002/(SICI)1097-0215(19971021)74:5<492::AID-IJC3>3.0.CO;2-Z, 9355970.
184. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immunohistochemical Staining for Transforming Growth Factor β1 Associates with Disease Progression inHuman Breast Cancer. Cancer Res 1992, 52:6949-6952.
185. Desruisseau S, Palmari J, Giusti C, Romain S, Martin PM, Berthois Y. Determination of TGF[beta]1 protein level in human primary breast cancers and its relationship withsurvival. Br J Cancer 2006, 94:239-246. 10.1038/sj.bjc.6602920, 2361106, 16404434.
186. Dalal BI, Keown PA, Greenberg AH. Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and tolymph node metastases of human mammary carcinoma. Am J Pathol 1993, 143:381-389. 1887030, 8393616.
187. Barlow J, Yandell D, Weaver D, Casey T, Plaut K. Higher stromal expression of transforming growth factor-beta Type II Receptors is associated with poorer prognosisbreast tumors. Breast Cancer Res Treat 2003, 79:149-159. 10.1023/A:1023918026437, 12825850.
188. Takenoshita S, Mogi A, Tani M, Osawa H, Sunaga H, Kakegawa H, Yanagita Y, Koida T, Kimura M, Fujita KI, et al. Absence of mutations in the analysis of coding sequences of the entire transforming growth factor-beta type II receptor gene in sporadic humanbreast cancers. Oncol Rep 1998, 5:367-371.
189. Kalkhoven E, Roelen BA, De Winter JP, Mummery CL, Van Den E-V, Raaij AJ, Van Der Saag PT, Van Der Burg B. Resistance to transforming growth factor beta and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ 1995, 6:1151-1161.
190. Chen T, Carter D, Garrigue-Antar L, Reiss M. Transforming Growth Factor β Type I Receptor Kinase Mutant Associated with Metastatic Breast Cancer. Cancer Res 1998, 58:4805-4810.
191. Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC. The type III TGF-β receptor suppresses breast cancer progression. J Clin Invest 2007, 117:206-217. 10.1172/JCI29293, 1679965, 17160136.
192. Xie W, Mertens JC, Reiss DJ, Rimm DL, Camp RL, Haffty BG, Reiss M. Alterations of smad signaling in human breast carcinoma are associated with poor outcome. Cancer Res 2002, 62:497-505.
193. Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, Iliopoulos D, Pilozzi E, Liu C-G, Negrini M, et al. E2F1-Regulated MicroRNAs Impair TGFβ-Dependent Cell-Cycle Arrest and Apoptosis in Gastric Cancer. Cancer Cell 2008, 13:272-286. 10.1016/j.ccr.2008.02.013, 18328430.
194. Park K, Kim SJ, Bang YJ, Park JG, Kim NK, Roberts AB, Sporn MB. Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in humangastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta. Proc Natl Acad Sci USA 1994, 91:8772-8776. 10.1073/pnas.91.19.8772, 44688, 8090721.
195. Hahm KB, Lee KM, Kim YB, Hong WS, Lee WH, Han SU, Kim MW, Ahn BO, Oh TY, Lee MH, et al. Conditional loss of TGF-beta signalling leads to increased susceptibility to gastrointestinal carcinogenesis in mice. Aliment Pharmacol Ther 2002, 16(Suppl 2):115-127.
196. Fu H, Hu Z, Wen J, Wang K, Liu Y. TGF-beta promotes invasion and metastasis of gastric cancer cells by increasing fascin1 expression via ERK and JNK signal pathways. Acta Biochim Biophys Sin (Shanghai) 2009, 41:648-656.
197. Shinto O, Yashiro M, Toyokawa T, Nishii T, Kaizaki R, Matsuzaki T, Noda S, Kubo N, Tanaka H, Doi Y, et al. Phosphorylated smad2 in advanced stage gastric carcinoma. BMC Cancer 2010, 10:652. 10.1186/1471-2407-10-652, 3001722, 21110833.
198. Han SU, Kim HT, Seong DH, Kim YS, Park YS, Bang YJ, Yang HK, Kim SJ. Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastriccancer. Oncogene 2004, 23:1333-1341. 10.1038/sj.onc.1207259, 14647420.
199. Yoo YA, Kang MH, Kim JS, Oh SC. Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the ALK5-Smad 3 pathway. Carcinogenesis 2008, 29:480-490.
200. Mamiya T, Yamazaki K, Masugi Y, Mori T, Effendi K, Du W, Hibi T, Tanabe M, Ueda M, Takayama T, Sakamoto M. Reduced transforming growth factor-beta receptor II expression in hepatocellular carcinoma correlates with intrahepatic metastasis. Lab Invest 2010, 90:1339-1345. 10.1038/labinvest.2010.105, 20531292.
201. Longerich T, Breuhahn K, Odenthal M, Petmecky K, Schirmacher P. Factors of transforming growth factor beta signalling are co-regulated in human hepatocellular carcinoma. Virchows Arch 2004, 445:589-596. 10.1007/s00428-004-1118-x, 15455231.
202. Yakicier MC, Irmak MB, Romano A, Kew M, Ozturk M. Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene 1999, 18:4879-4883. 10.1038/sj.onc.1202866, 10490821.
203. Yang YA, Zhang GM, Feigenbaum L, Zhang YE. Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation ofBcl-2. Cancer Cell 2006, 9:445-457. 10.1016/j.ccr.2006.04.025, 2708973, 16766264.
204. Yamamura Y, Hua X, Bergelson S, Lodish HF. Critical Role of Smads and AP-1 complex in transforming growth factor-β-dependent Apoptosis. J Biol Chem 2000, 275:36295-36302. 10.1074/jbc.M006023200, 10942775.
205. Mazzocca A, Fransvea E, Lavezzari G, Antonaci S, Giannelli G. Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinomagrowth through neo-angiogenesis regulation. Hepatology 2009, 50:1140-1151. 10.1002/hep.23118, 19711426.
206. Mazzocca A, Fransvea E, Dituri F, Lupo L, Antonaci S, Giannelli G. Down-regulation of connective tissue growth factor by inhibition of transforming growth factor betablocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology 2010, 51:523-534. 10.1002/hep.23285, 19821534.
207. Flechsig P, Dadrich M, Bickelhaupt S, Jenne J, Hauser K, Timke C, Peschke P, Hahn EW, Gröne HJ, Yingling J, et al. LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-β and BMP-associated proinflammatory andproangiogenic signals. Clin Cancer Res 2012, 18:3616-3627. 10.1158/1078-0432.CCR-11-2855, 22547771.
208. Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, Cohen A. High levels of transforming growth factor beta 1 correlate with disease progression in human coloncancer. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 1995, 4:549-554.
209. Yan Z, Winawer S, Friedman E. Two different signal transduction pathways can be activated by transforming growth factor beta 1 in epithelial cells. J Biol Chem 1994, 269:13231-13237.
210. Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, Tsui L-C, Bapat B, Gallinger S, Andrulis IL, et al. MADR2 Maps to 18q21 and Encodes a TGF[beta]-Regulated MAD-Related Protein That Is Functionally Mutated in Colorectal Carcinoma. Cell 1996, 86:543-552. 10.1016/S0092-8674(00)80128-2, 8752209.
211. Ku JL, Park SH, Yoon KA, Shin YK, Kim KH, Choi JS, Kang HC, Kim IJ, Han IO, Park JG. Genetic alterations of the TGF-beta signaling pathway in colorectal cancer cell lines: a novel mutation in Smad3 associated with the inactivation of TGF-beta-inducedtranscriptional activation. Cancer Lett 2007, 247:283-292. 10.1016/j.canlet.2006.05.008, 16828225.
212. Ando T, Sugai T, Habano W, Jiao Y-F, Suzuki K. Analysis of SMAD4/DPC4 gene alterations in multiploid colorectal carcinomas. J Gastroenterol 2005, 40:708-715. 10.1007/s00535-005-1614-z, 16082587.
213. Takagi Y, Kohmura H, Futamura M, Kida H, Tanemura H, Shimokawa K, Saji S. Somatic alterations of the DPC4 gene in human colorectal cancersin vivo. Gastroenterology 1996, 111:1369-1372. 10.1053/gast.1996.v111.pm8898652, 8898652.
214. Wang H, Rajan S, Liu G, Chakrabarty S. Transforming growth factor [beta] suppresses [beta]-catenin/Wnt signaling and stimulates an adhesion response in humancolon carcinoma cells in a Smad4/DPC4 independent manner. Cancer Lett 2008, 264:281-287. 10.1016/j.canlet.2008.01.039, 2474760, 18367323.
215. Ali NA, McKay MJ, Molloy MP. Proteomics of Smad4 regulated transforming growth factor-beta signalling in colon cancer cells. Mol Biosyst 2010, 6:2332-2332. 10.1039/c0mb00016g, 20862427.
216. Nikolic A, Kojic S, Knezevic S, Krivokapic Z, Ristanovic M, Radojkovic D. Structural and functional analysis of SMAD4 gene promoter in malignant pancreatic andcolorectal tissues: Detection of two novel polymorphic nucleotide repeats. Cancer Epidemiol 2011, 35:265-271. 10.1016/j.canep.2010.10.002, 21036691.
217. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science (New York, NY) 1995, 268:1336-1338.
218. Parsons R, Myeroff LL, Liu B, Willson JKV, Markowitz SD, Kinzler KW, Vogelstein B. Microsatellite Instability and Mutations of the Transforming Growth Factor β Type II Receptor Gene in Colorectal Cancer. Cancer Res 1995, 55:5548-5550.
219. Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, Neumann A, Brattain MG, Chang J, Kim SJ, et al. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res 1999, 59:320-324.
220. Liu XQ, Rajput A, Geng L, Ongchin M, Chaudhuri A, Wang J. Restoration of transforming growth factor-beta receptor II expression in colon cancer cells withmicrosatellite instability increases metastatic potentialin vivo. J Biol Chem 2011, 286:16082-16090. 10.1074/jbc.M111.221697, 3091217, 21454688.
221. Pasche B, Wisinski KB, Sadim M, Kaklamani V, Pennison MJ, Zeng Q, Bellam N, Zimmerman J, Yi N, Zhang K, et al. Constitutively decreased TGFBR1 allelic expression is a common finding in colorectal cancer and is associated with three TGFBR1 SNPs. J Exp Clin Cancer Res 2010, 29:57-57. 10.1186/1756-9966-29-57, 2890549, 20500843.
222. Gatza CE, Holtzhausen A, Kirkbride KC, Morton A, Gatza ML, Datto MB, Blobe GC. Type III TGF-β Receptor Enhances Colon Cancer Cell Migration and Anchorage- Independent Growth. Neoplasia 2011, 13:758-770. 3156666, 21847367.
223. Tian X, Du H, Fu X, Li K, Li A, Zhang Y. Smad4 restoration leads to a suppression of Wnt/[beta]-catenin signaling activity and migration capacity in human coloncarcinoma cells. Biochem Biophys Res Commun 2009, 380:478-483. 10.1016/j.bbrc.2009.01.124, 19284991.
224. Cottonham CL, Kaneko S, Xu L. miR-21 and miR-31 Converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem 2010, 285:35293-35302. 10.1074/jbc.M110.160069, 2975153, 20826792.
225. Furukawa T. Molecular pathology of pancreatic cancer: implications for molecular targeting therapy. Clin Gastroenterol H: Clin Prac J Am Gastroen Assoc 2009, 7:S35-S39.
226. Fujisawa H, Reis RM, Nakamura M, Colella S, Yonekawa Y, Kleihues P, Ohgaki H. Loss of heterozygosity on chromosome 10 is more extensive in primary (De Novo) than in secondary glioblastomas. Lab Invest 2000, 80:65-72. 10.1038/labinvest.3780009, 10653004.
227. Hahn SA, Shamsul Hoque ATM, Moskaluk CA, da Costa LT, Schutte M, Rozenblum E, Seymour AB, Weinstein CL, Yeo CJ, Hruban RH, Kern SE. Homozygous Deletion Map at 18q21.1 in Pancreatic Cancer. Cancer Res 1996, 56:490-494.
228. Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE. Genetic alterations of the transforming growth factor β receptor genes in pancreatic and biliaryadenocarcinomas. Cancer Res 1998, 58:5329-5332.
229. Pasche B, Kolachana P, Nafa K, Satagopan J, Chen YG, Lo RS, Brener D, Yang D, Kirstein L, Oddoux C, et al. TbetaR-I(6A) is a candidate tumor susceptibility allele. Cancer Res 1999, 59:5678-5682.
230. Smirne C, Camandona M, Alabiso O, Bellone G, Emanuelli G. [High serum levels of transforming growth factor-beta1, Interleukin-10 and Vascular endothelial growthfactor in pancreatic adenocarcinoma patients]. Minerva Gastroenterol Dietol 1999, 45:21-27.
231. Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, Chiao PJ. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancermetastasis. Mol Cancer Ther 2008, 7:829-840. 10.1158/1535-7163.MCT-07-0337, 3088432, 18413796.
232. Sterlacci W, Wolf D, Savic S, Hilbe W, Schmid T, Jamnig H, Fiegl M, Tzankov A. High transforming growth factor β expression represents an important prognostic parameter for surgically resected non-small cell lung cancer. Hum Pathol 2011, 43(3):339-349.
233. González-Santiago AE, Mendoza-Topete LA, Sánchez-Llamas F, Troyo-Sanromán R, Gurrola-Díaz CM. TGF-β1 serum concentration as a complementary diagnostic biomarker of lung cancer: establishment of a cut-point value. J Clin Lab Anal 2011, 25:238-243. 10.1002/jcla.20465, 21786325.
234. Zhang H-T, Chen X-F, Wang M-H, Wang J-C, Qi Q-Y, Zhang R-M, Xu W-Q, Fei Q-Y, Wang F, Cheng Q-Q, et al. Defective expression of transforming growth factor β Receptor Type II is associated with CpG methylated promoter in primary non-smallcell lung cancer. Clin Cancer Res 2004, 10:2359-2367. 10.1158/1078-0432.CCR-0959-3, 15073112.
235. Jiang X, Liu R, Lei Z, You J, Zhou Q, Zhang H. [Defective expression of TGFBR3 gene and its molecular mechanisms in non-small cell lung cancer cell lines]. Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer 2010, 13:451-457.
236. Jeon H-S, Dracheva T, Yang S-H, Meerzaman D, Fukuoka J, Shakoori A, Shilo K, Travis WD, Jen J. SMAD6 contributes to patient survival in non-small cell lung cancer and its knockdown reestablishes TGF-beta homeostasis in lung cancer cells. Cancer Res 2008, 68:9686-9692. 10.1158/0008-5472.CAN-08-1083, 19047146.
237. Xu C-C, Wu L-M, Sun W, Zhang N, Chen W-S, Fu X-N. Effects of TGF-β signaling blockade on human A549 lung adenocarcinoma cell lines. Molecular Medicine Reports 2011, 4:1007-1015.
238. Hu X, Cui D, Moscinski LC, Zhang X, Maccachero V, Zuckerman KS. TGFbeta regulates the expression and activities of G2 checkpoint kinases in human myeloidleukemia cells. Cytokine 2007, 37:155-162. 10.1016/j.cyto.2007.03.009, 17459720.
239. Jakubowiak A, Pouponnot C, Berguido F, Frank R, Mao S, Massague J, Nimer SD. Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. J Biol Chem 2000, 275:40282-40287. 10.1074/jbc.C000485200, 11032826.
240. Imai Y, Kurokawa M, Izutsu K, Hangaishi A, Maki K, Ogawa S, Chiba S, Mitani K, Hirai H. Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis. Oncogene 2001, 20:88-96. 10.1038/sj.onc.1204057, 11244507.
241. Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y, Hirai H. The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factorbeta-mediated growth inhibition of myeloid cells. Blood 1998, 92:4003-4012.
242. Jones L, Wei G, Sevcikova S, Phan V, Jain S, Shieh A, Wong JC, Li M, Dubansky J, Maunakea ML, et al. Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. J Exp Med 2010, 207:2581-2594. 10.1084/jem.20091071, 2989761, 21059853.
243. Lin HK, Bergmann S, Pandolfi PP. Cytoplasmic PML function in TGF-beta signalling. Nature 2004, 431:205-211. 10.1038/nature02783, 15356634.
244. Ernst T, La Rosée P, Müller MC, Hochhaus A. BCR-ABL mutations in chronic myeloid leukemia. Hematol Oncol Clin North Am 2011, 25:997-1008. v-vi, 10.1016/j.hoc.2011.09.005, 22054731.
245. Atfi A, Abécassis L, Bourgeade MF. Bcr-Abl activates the AKT/Fox O3 signalling pathway to restrict transforming growth factor-beta-mediated cytostatic signals. EMBO Rep 2005, 6:985-991. 10.1038/sj.embor.7400501, 1369182, 16113647.
246. Jonuleit T, van der Kuip H, Miething C, Michels H, Hallek M, Duyster J, Aulitzky WE. Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood 2000, 96:1933-1939.
247. Ogawa S, Kurokawa M, Tanaka T, Tanaka K, Hangaishi A, Mitani K, Kamada N, Yazaki Y, Hirai H. Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia. Leukemia 1996, 10:788-794.
248. Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S, Yazaki Y, Matsumoto K, Hirai H. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature 1998, 394:92-96. 10.1038/27945, 9665135.
249. Møller GM, Frost V, Melo JV, Chantry A. Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloidleukaemia. FEBS Lett 2007, 581:1329-1334. 10.1016/j.febslet.2007.02.048, 17349636.
250. Wolfraim LA, Fernandez TM, Mamura M, Fuller WL, Kumar R, Cole DE, Byfield S, Felici A, Flanders KC, Walz TM, et al. Loss of Smad3 in acute T-cell lymphoblastic leukemia. N Engl J Med 2004, 351:552-559. 10.1056/NEJMoa031197, 15295048.
251. Ford AM, Palmi C, Bueno C, Hong D, Cardus P, Knight D, Cazzaniga G, Enver T, Greaves M. The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells. J Clin Invest 2009, 119:826-836. 2662549, 19287094.
252. Scott SA, Kimura T, Dong WF, Ichinohasama R, Bergen S, Kerviche A, Sheridan D, DeCoteau JF. Methylation status of cyclin-dependent kinase inhibitor genes within the transforming growth factor beta pathway in human T-cell lymphoblasticlymphoma/leukemia. Leuk Res 2004, 28:1293-1301. 10.1016/j.leukres.2004.03.019, 15475071.
253. Mori N, Morishita M, Tsukazaki T, Giam CZ, Kumatori A, Tanaka Y, Yamamoto N. Human T-cell leukemia virus type I oncoprotein Tax represses Smad-dependent transforming growth factor beta signaling through interaction with CREB-bindingprotein/p300. Blood 2001, 97:2137-2144. 10.1182/blood.V97.7.2137, 11264182.
254. Lee DK, Kim BC, Brady JN, Jeang KT, Kim SJ. Human T-cell lymphotropic virus type 1 tax inhibits transforming growth factor-beta signaling by blocking theassociation of Smad proteins with Smad-binding element. J Biol Chem 2002, 277:33766-33775. 10.1074/jbc.M200150200, 12097320.
255. Arnulf B, Villemain A, Nicot C, Mordelet E, Charneau P, Kersual J, Zermati Y, Mauviel A, Bazarbachi A, Hermine O. Human T-cell lymphotropic virus oncoprotein Tax represses TGF-beta 1 signaling in human T cells via c-Jun activation: a potentialmechanism of HTLV-I leukemogenesis. Blood 2002, 100:4129-4138. 10.1182/blood-2001-12-0372, 12393612.
256. Shehata M, Schwarzmeier JD, Hilgarth M, Hubmann R, Duechler M, Gisslinger H. TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia. J Clin Invest 2004, 113:676-685. 351317, 14991065.
257. Kadin ME, Cavaille-Coll MW, Gertz R, Massagué J, Cheifetz S, George D. Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci USA 1994, 91:6002-6006. 10.1073/pnas.91.13.6002, 44125, 8016105.
258. Knaus PI, Lindemann D, DeCoteau JF, Perlman R, Yankelev H, Hille M, Kadin ME, Lodish HF. A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma. Mol Cell Biol 1996, 16:3480-3489. 231343, 8668164.
259. Schiemann WP, Pfeifer WM, Levi E, Kadin ME, Lodish HF. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation bytransforming growth factor beta in a cutaneous T-cell lymphoma. Blood 1999, 94:2854-2861.
260. Nakahata S, Yamazaki S, Nakauchi H, Morishita K. Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-beta1-mediated growthsuppression in adult T-cell leukemia/lymphoma. Oncogene 2010, 29:4157-4169. 10.1038/onc.2010.172, 20514018.
261. Munoz O, Fend F, de Beaumont R, Husson H, Astier A, Freedman AS. TGFbetamediated activation of Smad1 in B-cell non-Hodgkin's lymphoma and effect on cellproliferation. Leukemia 2004, 18:2015-2025. 10.1038/sj.leu.2403485, 15470494.
262. Bakkebø M, Huse K, Hilden VI, Smeland EB, Oksvold MP. TGF-β-induced growth inhibition in B-cell lymphoma correlates with Smad1/5 signalling and constitutivelyactive p38 MAPK. BMC Immunol 2010, 11:57. 10.1186/1471-2172-11-57, 3006362, 21092277.
263. Chen G, Ghosh P, Osawa H, Sasaki CY, Rezanka L, Yang J, O'Farrell TJ, Longo DL. Resistance to TGF-beta 1 correlates with aberrant expression of TGF-beta receptor II in human B-cell lymphoma cell lines. Blood 2007, 109:5301-5307. 10.1182/blood-2006-06-032128, 1890833, 17339425.
264. Rai D, Kim SW, McKeller MR, Dahia PL, Aguiar RC. Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc Natl Acad Sci USA 2010, 107:3111-3116. 10.1073/pnas.0910667107, 2840369, 20133617.
265. Douglas RS, Capocasale RJ, Lamb RJ, Nowell PC, Moore JS. Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factorbeta. Blood 1997, 89:941-947.
266. Lagneaux L, Delforge A, Bron D, Massy M, Bernier M, Stryckmans P. Heterogenous response of B lymphocytes to transforming growth factor-beta in B-cell chroniclymphocytic leukaemia: correlation with the expression of TGF-beta receptors. Br J Haematol 1997, 97:612-620. 10.1046/j.1365-2141.1997.792715.x, 9207409.
267. DeCoteau JF, Knaus PI, Yankelev H, Reis MD, Lowsky R, Lodish HF, Kadin ME. Loss of functional cell surface transforming growth factor beta (TGF-beta) type 1 receptorcorrelates with insensitivity to TGF-beta in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1997, 94:5877-5881. 10.1073/pnas.94.11.5877, 20874, 9159168.
268. Schiemann WP, Rotzer D, Pfeifer WM, Levi E, Rai KR, Knaus P, Kadin ME. Transforming growth factor-beta (TGF-beta)-resistant B cells from chronic lymphocytic leukemia patients contain recurrent mutations in the signal sequence of thetype I TGF-beta receptor. Cancer Detect Prev 2004, 28:57-64. 10.1016/j.cdp.2003.11.001, 15041079.
269. Jelinek DF, Tschumper RC, Stolovitzky GA, Iturria SJ, Tu Y, Lepre J, Shah N, Kay NE. Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Mol Cancer Res 2003, 1:346-361.
270. Lotz M, Ranheim E, Kipps TJ. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med 1994, 179:999-1004. 10.1084/jem.179.3.999, 2191408, 8113691.
271. Spender LC, Inman GJ. TGF-beta induces growth arrest in Burkitt lymphoma cells via transcriptional repression of E2F-1. J Biol Chem 2009, 284:1435-1442.
272. Inman GJ, Allday MJ. Resistance to TGF-beta1 correlates with a reduction of TGFbeta type II receptor expression in Burkitt's lymphoma and Epstein-Barr virustransformedB lymphoblastoid cell lines. J Gen Virol 2000, 81:1567-1578.
273. Urashima M, Ogata A, Chauhan D, Hatziyanni M, Vidriales MB, Dedera DA, Schlossman RL, Anderson KC. Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. Blood 1996, 87:1928-1938.
274. Hayashi T, Hideshima T, Nguyen AN, Munoz O, Podar K, Hamasaki M, Ishitsuka K, Yasui H, Richardson P, Chakravarty S, et al. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth inthe bone marrow microenvironment. Clin Cancer Res 2004, 10:7540-7546. 10.1158/1078-0432.CCR-04-0632, 15569984.
275. Amoroso SR, Huang N, Roberts AB, Potter M, Letterio JJ. Consistent loss of functional transforming growth factor beta receptor expression in murineplasmacytomas. Proc Natl Acad Sci USA 1998, 95:189-194. 10.1073/pnas.95.1.189, 18171, 9419351.
276. Fernandez T, Amoroso S, Sharpe S, Jones GM, Bliskovski V, Kovalchuk A, Wakefield LM, Kim SJ, Potter M, Letterio JJ. Disruption of transforming growth factor beta signaling by a novel ligand-dependent mechanism. J Exp Med 2002, 195:1247-1255. 10.1084/jem.20011521, 2193757, 12021305.
277. de Carvalho F, Colleoni GW, Almeida MS, Carvalho AL, Vettore AL. TGFbetaR2 aberrant methylation is a potential prognostic marker and therapeutic target inmultiple myeloma. Int J Cancer 2009, 125:1985-1991. 10.1002/ijc.24431, 19548309.
278. Lambert KE, Huang H, Mythreye K, Blobe GC. The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myelomacells. Mol Biol Cell 2011, 22:1463-1472. 10.1091/mbc.E10-11-0877, 3084669, 21411633.
279. Kyrtsonis MC, Repa C, Dedoussis GV, Mouzaki A, Simeonidis A, Stamatelou M, Maniatis A. Serum transforming growth factor-beta 1 is related to the degree of immunoparesis in patients with multiple myeloma. Med Oncol 1998, 15:124-128. 10.1007/BF02989591, 9789221.
280. Cook G, Campbell JD, Carr CE, Boyd KS, Franklin IM. Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in Tlymphocytes. J Leukoc Biol 1999, 66:981-988.
281. Matsumoto T, Abe M. TGF-β-related mechanisms of bone destruction in multiple myeloma. Bone 2011, 48:129-134. 10.1016/j.bone.2010.05.036, 20570621.